Current as of December 10, 2023
Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of response.
- Patients with a histologic diagnosis confirmed from a pretreatment biopsy at the Laboratory of Pathology, NCI of one of the following entities: Diffuse small Lymphocytic Lymphoma; Follicular, Small Cleaved cell Lymphoma; Follicular, Mixed Small Cleaved and Large Cell Lymphoma; Follicular Large Cell Lymphoma; Diffuse, Intermediately Differentiated Lymphocytic Lymphoma; Diffuse, Small Cleaved Cell Lymphoma; Diffuse, Mixed Small and Large Cell Lymphoma; Diffuse, Large Cell Lymphoma; Large Cell Immunoblastic Lymphoma; Small Noncleaved Cell Lymphoma.
- Presence of CD22 antigen on at least 30 percent of tumor cells.
- Presence of objectively measurable sites of disease. Bone marrow positivity and circulating tumor cells in the peripheral blood will be considered evaluable but not measurable disease.
- No patients with purely B-cell Lymphosarcoma cell leukemia without nodal or soft tissue involvement.
- No patients with B-cell chronic lymphocytic leukemia, or B-cell or pre-B-cell acute lymphocytic leukemia, and hairy cell leukemia.
- Patients with objectively measurable disease outside a radiation port or disease which has clearly progressed within a radiation port.
- HIV negative.
- No CNS disease.
- No pulmonary parenchymal disease.
- Pleural effusions or ascites may be present.
- Patients with progression of disease despite at least one standard combination chemotherapy regimen.
- No chemotherapy for at least two weeks prior to entry.
- Patients who do not desire or are not candidates for autologous or allogeneic bone marrow transplantation procedures.
- Life expectancy of at least 3 months
- Creatinine clearance greater than 60 cc per minute.
- Total bilirubin less than 1.5 mg/dl.
- SGPT less than 2 times the upper limit of normal.
- Albumin greater than 75 percent of the lower limit of normal.
- If prior treatment with doxorubicin, the radionuclide or echocardiogram ejection fraction shall be at least 35 percent.
- Performance status 0-2.
- Not in need of current radiation therapy to alleviate local problems.
- No prior exposure to murine antibodies.
- No need for current corticosteroid treatment.
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients